Safety and tolerability of tildrakizumab, an anti–interleukin-23p19 monoclonal antibody, in patients with chronic plaque psoriasis over two years of treatment: Results from long-term extensions of two phase III clinical studies (reSURFACE 1 and reSURFACE 2)
2018 ◽
Vol 79
(3)
◽
pp. AB251
Keyword(s):
2018 ◽
Vol 2
◽
pp. S4
◽
Keyword(s):
Keyword(s):
2014 ◽
Vol 71
(3)
◽
pp. 484-492
◽
Keyword(s):
2016 ◽
Vol 74
(5)
◽
pp. 841-850
◽
2019 ◽
Vol 181
(6)
◽
pp. 1177-1189
◽
Keyword(s):
2007 ◽
Vol 56
(2)
◽
pp. AB5
Keyword(s):
2017 ◽
Vol 51
(9)
◽
pp. 804-810
◽
Keyword(s):
2014 ◽
Vol 26
(12)
◽
pp. 1792-1801
◽
Keyword(s):